stockrowGinkgo Bioworks Holdings, Inc. (DNA) vs Lexicon Pharmaceuticals, Inc. (LXRX)
- Ginkgo Bioworks Holdings, Inc. DNA 11.19 +12.35%
- Lexicon Pharmaceuticals, Inc. LXRX 1.79 +11.18%
Ginkgo Bioworks Holdings, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Ginkgo Bioworks Holdings, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($716.4M and $670.7M). Lexicon Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −45.6% against −51.5%. Lexicon Pharmaceuticals, Inc. has the higher net margin (−161.8% vs −260.0%) and the higher return on invested capital (−109.1% vs −161.9%). Across the 18 metrics below, Lexicon Pharmaceuticals, Inc. leads on 12 and Ginkgo Bioworks Holdings, Inc. on 6.
Valuation
Profitability
| Metric | DNA | LXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 80.55% | 98.89% | 68.51% |
| Operating margin | (273.61%) | (147.42%) | 0.00% |
| Net margin | (259.96%) | (161.80%) | 0.00% |
| Free cash flow margin | (155.75%) | (127.76%) | 0.00% |
| Return on equity | (56.29%) | (43.91%) | (51.96%) |
| Return on assets | (26.19%) | (27.84%) | (46.06%) |
| Return on invested capital | (161.94%) | (109.13%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack